05:31 PM EDT, 06/25/2024 (MT Newswires) -- Annexon ( ANNX ) reported late Tuesday "positive" results from a phase 3 trial of ANX005 in Guillain-Barre Syndrome.

The company said ANX005-treated patients showed "faster and more complete recovery" from week 1 through week 26 on primary and multiple pre-specified endpoints. The results were presented at the Peripheral Nerve Society meeting in Canada.

Further, the company said that two-and-a-half times more ANX005-treated patients returned to a pre-disease state of health over placebo by week 26, increasing over time.

It also said ANX005's beneficial impact was "larger" in patients with North American and European baseline characteristics across some critical measures of disability and muscle strength.

Price: 4.6100, Change: +0.03, Percent Change: +0.66